Australia's most trusted
source of pharma news
Thursday, 03 April 2025
Posted 2 April 2025 PM
An Aussie start-up is accelerating its entry into the US market by launching a compounded version of its erectile dysfunction nasal spray.
LTR Pharma is launching nasal spray Roxus, which has the same active ingredient as its main product Spontan, to be delivered via the 503(a)-compounding pharmacy pathway, which is marketed as personalised care in the United States. It's expected to be released in the first half of next year, once stability and shelf-life are determined.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.